Medical
Health
Therapy

Invitae

$24.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.35 (1.45%) Today
+$0.35 (1.45%) Today

Why Robinhood?

You can buy or sell Invitae and other stocks, options, ETFs, and crypto commission-free!

About

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. Read More The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Employees
788
Headquarters
San Francisco, California
Founded
2010
Market Cap
1.83B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.23M
High Today
$24.74
Low Today
$24.00
Open Price
$24.29
Volume
103.17K
52 Week High
$25.20
52 Week Low
$4.35

Collections

Medical
Health
Therapy
2015 IPO

News

The Motley FoolMar 18

About to Buy Penny Stocks? Look at These 3 Companies First

For investors looking for big gains in the stock market, penny stocks can be enticing. But the low cost of a stock doesn't necessarily lead to big gains, and all too often penny stocks just end up going lower. For investors looking for big gains, there's a lot to like about MGM Resorts International (NYSE:MGM), Invitae (NYSE:NVTA), and Denbury Resources (NYSE:DNR). Here's why three of our Motley Fool contributors think these are much better than penny stocks. A better gamble than penny stocks Travis Hoiu...

3,642
PR NewswireMar 14

Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference

SAN FRANCISCO, March 14, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City.

76
The Motley FoolMar 11

Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February

What happened February was a great month for genetic testing stocks. Shares of Invitae (NYSE:NVTA) paced the pack with a monthly gain of 42.9%, according to data provided by S&P Global Market Intelligence. That was followed by NeoGenomics (NASDAQ:NEO) and Myriad Genetics (NASDAQ:MYGN), which rose 17.9% and 10.1%, respectively. Each stock soared on the heels of impressive quarterly operating results. The industry has long been a source of eye-popping growth, but is now harboring multiple profitable busines...

894

Earnings

-$0.78
-$0.65
-$0.53
-$0.40
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.